Breast Cancer
Clinical Trials
1) Up to 3 lines of post-adjuvant or neoadjuvant therapy for TNBC/AYALA: AL-TNBC-01: A Phase 2, Multicenter, Open-label study of AL101 Monotherapy in Patients with Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer
2) First line for locally advanced/ metastatic ER+ HER2 Neg/ BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GD9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with ER+, HER2 Neg Locally Advanced or Metastatic Breast Cancer
3) First and Second line of therapy (dependent upon monotherapy or combination therapy/Zeno 001: A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination with Palbociclib in Subjects with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer.
4) First line advanced/metastatic ER+ HER2 Neg ZENO 003 (ON HOLD): A Phase 1B Study of ZN-c5 in Combination with Abemaciclib in Patients with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
5) WO42633: A Phase 3, Randomized, Double Blind, Placebo Controlled Clinical Trail To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab OR Placebo And Trastuzumab Emtansine For HER2-Postive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy.
6) eMonoarch I3Y-MC-JPCW USO#20364: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in patients with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2 Targeted Therapy
Send UsA Message
Early-Stage Breast Cancer Characteristics and Treatment Options
Early-Stage Breast Cancer Characteristics and Treatment OptionsA rise in early-stage breast cancer diagnosis may result from better screening technology and a raised awareness of the importance of annual mammograms. An early-stage breast cancer diagnosis is contained...
Game Changing Neoadjuvant Lung Trial Enrolls the Most People in the World
Charleston Oncology’s Clinical Trials most recent non–small cell lung cancer trial enrolled the most people in the world. Gene Saylors, MD, oncologist and hematologist at Charleston Oncology, will present the positive findings at the American Association for Cancer Research 2022 Annual Meeting. “When administering a new trial, we are always cautiously optimistic,” says Dr. Gene Saylors. “The positive results of this Neoadjuvant Lung Trial resulted in rapid FDA approval due to its impressive outcomes.”
Lowcountry doctors, patients helped secure ‘game-changer’ cancer treatment approval
Clinical trials for a newly-approved cancer treatment for lung cancer in the Lowcountry helped get the drug ready for people around the world, Lowcountry medical officials say.
Lowcountry Breast Cancer Survivors On Finding The Right Oncology Practice
How should one go about finding the right oncology practice? We interviewed ten Lowcountry breast cancer patients to get their perspectives and advice.
Sarcoma and Bone Cancer Awareness
July is Sarcoma and Bone Cancer Awareness Month. Sarcomas are a rare group of cancers in which malignant cells form in the bones or soft tissues of the body.
May is Skin Cancer Awareness Month
Melanoma is a type of skin cancer that develops when melanocytes start to grow out of control. Watch a video to learn more about melanoma from Dr. Charles S. Holladay.
